# R1 Clinical-Safety Review — numb_chin_syndrome

VERDICT: APPROVE

Confidence: 90. goldens changed: no (intended: n/a — narrative KB content, no engine/regression outputs touched).

## Summary
Draft management narrative for numb chin syndrome (mental neuropathy). No adversarial `.verdict.md`
exists at the sidecar path, so there are no still-present adversarial ISSUES to gate on. The draft
is transparently self-flagged: DeVita has no dedicated section for this entity, and EVERY clinical
claim is explicitly relabelled "general oncology standard, not from DeVita's section on this disease."
That is exactly the relabelling the R1 mandate permits for uncontroversial standard-of-care claims,
and it removes any DeVita mis-attribution risk.

## 1. Safety — PASS
- Core framing is correct and safe: numb chin syndrome is treated as a red-flag sign of underlying
  malignancy (metastatic / leptomeningeal), not an entity treated in isolation. This is the clinically
  protective message.
- No absolute/definitive claims that overstep decision-support. Language is hedged throughout
  ("typically," "can be used," "should prompt," "reviewed by a clinician before publication").
- No harmful directive. Benign causes (dental infection, osteomyelitis, sickle-cell vaso-occlusion)
  are explicitly required to be excluded, and oncologic therapy is correctly stated to have no role there.
- Neuropathic analgesia named only as a drug class (gabapentinoid) as add-on symptomatic relief that
  does not alter the oncologic plan — no unsafe interaction or override.

## 2. Grounding — PASS
- No claim is attributed to DeVita; the draft states the targeted DeVita search found only mental-nerve
  perineural invasion in the lip/oral-cavity chapter (a different context) and declines to cite it for
  this entity. No fabricated or outdated regimen.
- Clinical content matches accepted standard of care: MRI of the full skull-base-to-mandible nerve
  pathway, OPG to exclude benign local disease, CSF cytology for suspected leptomeningeal spread,
  systemic staging; breast/prostate carcinoma and lymphoid/leukemic infiltration as the most common
  causes; cause-directed treatment with local RT for symptomatic deposits and systemic therapy matched
  to the primary. All uncontroversial and correctly generalized.

## 3. Dose-Free — PASS
- No mg, mg/m2, AUC, or numbered schedule. Systemic options named only as classes/modalities
  ("hormonal therapy, chemotherapy, targeted or antibody-based agents, or an anthracycline- or
  platinum-based regimen"). Analgesia named as class only. Draft explicitly states doses/schedules
  are omitted per KB convention. Confirmed clean.

## 4. Scope — PASS
- Consistently framed as decision-support, not a directive. Refer-out triggers to oncology/neuro-oncology/
  maxillofacial/radiation oncology are appropriate. The "Omitted for lack of grounding" section correctly
  declines to invent regimen names, response rates, survival stats, or a staging-linked algorithm.

## 5. Adversarial flags — N/A
- No `.verdict.md` at the sidecar path. Nothing to carry forward or block on.

## Non-blocking note (Important, does not gate)
- The draft carries a self-imposed "needs manual sourcing" flag and relies entirely on "general oncology
  standard" attribution. That is acceptable for publication here because the claims are uncontroversial
  standard-of-care and are honestly labelled as general standard (not DeVita-specific). Before final
  publish, confirm the KB renderer preserves the "general oncology standard" qualifier and does not
  auto-stamp a DeVita citation onto this field — an auto-citation would convert a clean draft into a
  mis-attribution.

Blocking (Critical): none.
Important: source-qualifier must survive rendering (see note).
Advisory: none.
